FIELD: medicine.
SUBSTANCE: invention relates to the field of renal cell vesicle research and concerns a method of determining a renal cell vesicle as regenerative. Disclosed method involves determining whether expression of at least one compound in vesicles is increased or decreased compared to vesicles secreted by non-subcultured primary renal cells, where at least one compound contains one or more CD326, CD40, CD42a, CD44, CD49e and/or SSEA-4, and determining vesicle as regenerative, if at least one compound is CD326, CD40, CD44 and/or CD49e and expression of at least one compound in vesicle is increased and/or at least one compound is CD42a and/or SSEA-4 and expression of at least one compound in the vesicle is reduced.
EFFECT: method enables determining whether a renal cell vesicle is regenerative.
13 cl, 16 tbl, 3 ex, 19 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING KIDNEY DISEASE IN SUBJECTS WITH RENAL AND/OR URINARY TRACT ABNORMALITIES | 2020 |
|
RU2823980C2 |
| IMMUNOLOGICALLY PRIVILEGED BIOACTIVE KIDNEY CELLS FOR TREATMENT OF KIDNEY DISEASE | 2018 |
|
RU2816753C2 |
| USE OF microRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSTICS AND TREATMENT | 2014 |
|
RU2644247C2 |
| EXTRACELLULAR VESICLES FOR INHALATION | 2019 |
|
RU2799315C2 |
| EXO-SOMATIC BIOMARKERS | 2015 |
|
RU2712223C2 |
| VESICLES CONTAINING PTEN INHIBITOR AND THEIR USE | 2019 |
|
RU2800729C2 |
| DRUG FOR TREATMENT OF TISSUE FIBROSIS BASED ON COMPONENTS OF SECRETOME OF MESENCHYMAL STROMAL CELLS, METHOD FOR OBTAINING AND APPLYING REMEDY | 2020 |
|
RU2766707C1 |
| TUMOR EXTRACELLULAR VESICLES FOR TREATMENT OF ORGAN FAILURE | 2022 |
|
RU2791356C1 |
| PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS OF TREATING TUMORS | 2019 |
|
RU2810906C2 |
| METHOD AND DEVICE FOR RECOVERING EXTRACELLULAR VESICLES FROM BIOLOGICAL FLUIDS BY MEANS OF CASCADE ULTRAFILTRATION | 2017 |
|
RU2745613C1 |
